New USP Standards Guide Prescription Container Labels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New USP Standards Guide Prescription Container Labels


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeial Convention (USP) released standards that, for the first time, provide a universal approach to organizing labels for prescription containers dispensed by pharmacists. The new standards aim to eliminate the variability that currently exists between pharmacies across the US and improve patient understanding of medication instructions by giving direction for optimal format, appearance, content, and language.

“Lack of universal standards for labeling on dispensed prescription containers is a root cause for patient misunderstanding, nonadherence, and medication errors,” said Joanne G. Schwartzberg, MD, director of aging and community health for the American Medical Association and a member of the USP Nomenclature, Safety, and Labeling Expert Committee, which was responsible for the new standard, in an Oct. 9, 2012, press release. “With an aging and increasingly diverse population, and people utilizing a growing number of medications, the risks are more pronounced today than ever,” said Schwartzberg. The USP standards will promote patient understanding of medication instructions, she notes.

The standards explain how to create labels that reflect how most patients seek out and understand instructions. The standards include detailed instructions for how to:

  • Emphasize instructions and information important to patients
  • Improve readability
  • Give explicit instructions
  • Include purpose for use
  • Address limited English proficiency
  • Address visual impairment.

The final version of the standard will be published in November 2012, and will incorporate changes based on feedback on the draft version, which was released for public comment in December 2011. The boards of pharmacy in individual states may choose to adopt the standard into their regulations. The National Association of Boards of Pharmacy passed a resolution in May 2012 supporting state boards in requiring a standardized label.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here